Cipla (CIPLA) Stock Overview
Manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for CIPLA from our risk checks.
CIPLA Community Fair Values
Create NarrativeSee what 40 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cipla Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,331.50 |
| 52 Week High | ₹1,673.00 |
| 52 Week Low | ₹1,281.70 |
| Beta | -0.050 |
| 1 Month Change | -7.18% |
| 3 Month Change | -13.09% |
| 1 Year Change | -8.77% |
| 3 Year Change | 29.81% |
| 5 Year Change | 64.92% |
| Change since IPO | 41,162.09% |
Recent News & Updates
Recent updates
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
Jan 28
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
Jan 17We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Dec 29Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
Nov 20Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Nov 02Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
Sep 24Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Sep 06Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Jul 13Here's Why Cipla (NSE:CIPLA) Can Manage Its Debt Responsibly
Jun 03Earnings Beat: Cipla Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 16Cipla Limited (NSE:CIPLA) Investors Are Less Pessimistic Than Expected
Apr 15With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case
Mar 25These 4 Measures Indicate That Cipla (NSE:CIPLA) Is Using Debt Safely
Feb 17
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.Shareholder Returns
| CIPLA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.1% | 0.6% | -0.4% |
| 1Y | -8.8% | 4.4% | 11.0% |
Return vs Industry: CIPLA underperformed the Indian Pharmaceuticals industry which returned 4.4% over the past year.
Return vs Market: CIPLA underperformed the Indian Market which returned 11% over the past year.
Price Volatility
| CIPLA volatility | |
|---|---|
| CIPLA Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stable Share Price: CIPLA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: CIPLA's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1935 | 30,313 | Umang Vohra | www.cipla.com |
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry.
Cipla Limited Fundamentals Summary
| CIPLA fundamental statistics | |
|---|---|
| Market cap | ₹1.08t |
| Earnings (TTM) | ₹45.46b |
| Revenue (TTM) | ₹279.67b |
Is CIPLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CIPLA income statement (TTM) | |
|---|---|
| Revenue | ₹279.67b |
| Cost of Revenue | ₹97.36b |
| Gross Profit | ₹182.31b |
| Other Expenses | ₹136.85b |
| Earnings | ₹45.46b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 56.28 |
| Gross Margin | 65.19% |
| Net Profit Margin | 16.26% |
| Debt/Equity Ratio | 1.4% |
How did CIPLA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/14 10:26 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cipla Limited is covered by 63 analysts. 37 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Tinani | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Ashwin Mehta | Ambit Capital |